The role of vitamin D in prostate cancer (Q31943361)

5 July 2017

1 reference

title

The role of vitamin D in prostate cancer (English)

1 reference

5 July 2017

0 references

1 reference

Zhao XY

1 reference

5 July 2017

Feldman D

series ordinal

1 reference

5 July 2017

publication date

1 March 2001

1 reference

5 July 2017

1 reference

5 July 2017

1 reference

5 July 2017

issue

3-5

1 reference

5 July 2017

page(s)

293-300

1 reference

5 July 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Molecular genetics and epidemiology of prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

An investigation of the familial aspects of carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Evidence for alteration of the vitamin D-endocrine system in blacks

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Epidemiologic evidence regarding predisposing factors to prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

The androgen receptor in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

STUDIES ON PROSTATIC CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

The biology of hormone refractory prostate cancer. Why does it develop?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Vitamin D: a modulator of cell proliferation and differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Cloning and expression of full-length cDNA encoding human vitamin D receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

The steroid and thyroid hormone receptor superfamily

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

The nuclear vitamin D receptor: biological and molecular regulatory properties revealed.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Transcriptional targets of the vitamin D3 receptor-mediating cell cycle arrest and differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Studies on the human prostatic cancer cell line LNCaP.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Androgen-repressed phenotype in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Distinct conformational changes induced by 20-epi analogues of 1 alpha,25-dihydroxyvitamin D3 are associated with enhanced activation of the vitamin D receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2800%2900164-1

7 January 2021

10.1016/S0039-128X(00)00164-1

Identifiers

DOI

1 reference

5 July 2017

1 reference